 DUBLIN, Ireland, July 07, 2021 GLOBE NEWSWIRE -- Avadel Pharmaceuticals plc Nasdaq: AVDL, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Wednesday, July 14 at 11:00 a.m. ET. 